Tsiami, Foteini http://orcid.org/0009-0001-6070-0434
Lago, Chiara http://orcid.org/0000-0002-1317-7847
Pozza, Noemi
Piccioni, Federica http://orcid.org/0000-0003-1210-3210
Zhao, Xuesong http://orcid.org/0000-0003-3007-7124
Lülsberg, Fabienne
Root, David E. http://orcid.org/0000-0001-5122-861X
Tiberi, Luca http://orcid.org/0000-0002-5983-3782
Kool, Marcel http://orcid.org/0000-0002-6557-5468
Schittenhelm, Jens http://orcid.org/0000-0002-9168-6209
Bandopadhayay, Pratiti http://orcid.org/0000-0002-4175-4760
Segal, Rosalind A. http://orcid.org/0000-0001-9850-8432
Tabatabai, Ghazaleh http://orcid.org/0000-0002-3542-8782
Merk, Daniel J. http://orcid.org/0000-0003-2935-6919
Funding for this research was provided by:
Wilhelm Sander-Stiftung (2022.094.1)
German Research Foundation (EXC 2180-390900677)
Dana-Farber Pediatric Low-Grad Glioma Program
Universitätsklinikum Tübingen
Article History
Received: 15 April 2024
Accepted: 9 July 2024
First Online: 7 August 2024
Declarations
:
: Not applicable.
: Not applicable.
: Ghazaleh Tabatabai has served on advisory boards (Bayer, Boehringer Ingelheim, CureVac, Miltenyi Biomedicine, Novocure), as a consultant (Bayer, Boehringer Ingelheim, CureVac), as steering committee member in non-interventional trials (Bayer, Novocure), as a speaker (Novocure, Servier), and financial compensation for all these activities was provided as institutional funding to the University Hospital Tübingen. David E. Root receives research funding from members of the Functional Genomics Consortium (Abbvie, BMS, Jannsen, Merck, Vir), and is a director of Addgene, Inc.